ASAvner Shemer

Avner Shemer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Avner Shemer has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prolonging the Efficacy of Botulinum Toxin A Using a Novel Toxin Mimetic Complex and Peptide Formulation

    by Riad Kassem, Tomer Mimouni, Lee Magal, Ziad Khamaysi, Avner Shemer

    Background: Botulinum toxin type A (BTX‐A) is the cornerstone for treating dynamic wrinkles; however, it requires reinjection every 3–4 months. Adjunctive topical creams that mimic the effect of BTX‐A and enhance its action may prolong treatment intervals. Objectives: To evaluate the efficacy of a novel formulation containing Subderma‐Complex (arginine, niacinamide, and over‐the‐counter neuromodulating peptides, including: Munapsys, X50 Myocept, Syn‐Ake, and Argireline) in extending the duration of BTX‐A's effect. Methods & Materials: Subjects with moderate‐to‐severe facial wrinkles and a history of regular BTX‐A use applied the Subderma‐Complex serum and creams daily following BTX‐A injection. Reinjection was triggered by the reappearance of the first wrinkle. Outcomes were measured across five visits using the Investigator's Global Assessment, Subject Self‐Assessment, and instrumental analysis (VisioFace Lite). Results: Data from 15 participants were analyzed. The mean reinjection interval increased by 65.2%, from 13.5 ± 1.9 weeks at baseline to 22.3 ± 3.6 weeks following topical treatment ( p < 0.001). Both investigator and patient assessments showed significant reductions in wrinkle severity and improvements in skin quality ( p < 0.001). However, the small sample size and lack of a control group limit the generalizability of the findings. Conclusions: Daily application of a Subderma‐Complex formulation was well‐tolerated and significantly prolonged BTX‐A efficacy, potentially reducing reinjection frequency.

  • Open Access

    Genetic, immunological and clinical assessment of isolated chronic recalcitrant dermatophytosis: a prospective study

    by Eran Galili, Aviv Barzilai, Atar Lev, Sharon Amit, Ortal Barel, Irit Lubitz, Zeala Gazit, Anna Lyakhovitsky, Raz Somech, Avner Shemer

    Background: Chronic recalcitrant dermatophyte infection (CRDI) remains poorly understood, with limited research on its genetic, immunological and treatment aspects. Objectives: To investigate the genetic and immunological profiles, clinical characteristics and treatment outcomes in otherwise healthy patients with CRDI. Methods: This was a prospective study of patients with isolated superficial dermatophyte infections persisting for > 5 years and refractory to at least three oral antifungal agents. Whole-exome sequencing, interleukin (IL)-17 quantification and lymphocyte subset analysis were performed. Results: Of 5910 patients with superficial cutaneous fungal infections, 11 (10 men; 91%) with a mean (SD) disease duration of 26.4 (8.7) years were included in this study. All patients presented with extensive dermatophytosis, involving a mean (SD) of 5.6 (1.4) skin and nail sites. Immune alterations were identified in 55% (n = 6/11) of the patients, including three with monogenic immunodeficiency mutations (CARD9 and FOXN1), one with acquired immunodeficiency (Good syndrome) and two with isolated IL-17 deficiencies. Most patients (n = 10/11) showed a partial clinical response to continuous oral antifungal therapy, while only one patient remained a complete responder after discontinuing treatment. Conclusions: CRDI is a rare condition in patients with superficial cutaneous fungal infections. Genetic and immunological evaluation for immunodeficiency should be considered in patients with CRDI. Management may require prolonged or lifelong oral antifungal therapy.


  • Age of onset defines two distinct profiles of atopic dermatitis in adults

    by Paola Facheris, Joel Correa Da Rosa, Angel D. Pagan, Michael Angelov, Ester Del Duca, Grace Rabinowitz, Pedro Jesús Gómez‐Arias, Camille Rothenberg‐Lausell, Yeriel D. Estrada, Swaroop Bose, et al.

    Background: The incidence of adult‐onset atopic dermatitis (AOAD) is increasing. However, the unique characteristics of AOAD compared to pediatric‐onset AD persisting into adulthood (POAD) are underexplored, hampering the development of targeted‐therapeutics for this growing population. We thus assessed the profile of AOAD in skin and blood compared to that of POAD.Methods: We collected skin biopsies and blood from adults with AOAD, POAD, and healthy controls (n = 15 in each group). Skin samples were analyzed by RNA sequencing, qRT‐PCR, and immunohistochemistry, and Olink Proseek multiplex assay was used to identify the serum proteomic profile.Results: Compared to healthy controls, both AOAD and POAD showed cutaneous immune and barrier dysregulations with a shared Th2/Th22 hyperactivation. Overall, POAD showed greater inflammation in lesional skin, with more prominent expression of Th2/Th17/Th22 markers (CCL17/22, S100A8/9, IL‐36A, PI3/Elafin, DEFB4) in POAD compared to AOAD (p‐value < .05). In contrast, higher Th1‐(IFN‐γ, IL‐2, IL‐15, CCL5) upregulation and Th1‐skewing were seen in AOAD. The epidermal barrier was also more compromised in POAD, with greater epidermal hyperplasia and lower expression of markers related to terminal differentiation, lipids, and cell adhesion. In parallel with increased rates of cardiovascular comorbidities, AOAD demonstrated many more significantly dysregulated proteins in serum (n = 148) compared to POAD (n = 86), including pro‐inflammatory and cardiovascular‐risk markers. Th1‐related products showed significant correlations between their skin and blood expressions only in AOAD subjects.Conclusion: Age‐of‐onset delineates two distinct endophenotypes in adult AD potentially suggesting the need for broader (beyond Th2) therapeutic targeting in AOAD.


  • Nail sampling in onychomycosis: comparative study of curettage from three sites of the infected nail

    by Avner Shemer, Henri Trau, Batya Davidovici, Marcelo H. Grunwald, Boaz Amichai

    Summary: Background: Onychomycosis is a common problem.Obtaining accurate laboratory test results before treatment is important in clinical practice since the treatment of onychomycosis requires expensive oral antifungal therapy with potentially serious side‐effects. The purpose of this study was to compare results of curettage technique of nail sampling in the diagnosis of onychomycosis from three different sites of the affected nail to establish the best location of sampling. Patients and Methods: We evaluated 194 patients suffering from distal and lateral subungual onychomycosis (DLSO) and lateral subungual onychomycosis (LSO) using curettage technique. KOH examination and fungal culture were used for detection and identification of fungal infection. Results: The culture sensitivity improves significantly as the location of the sample is more proximal. Trichophyton rubrum was by far the most common pathogen detected from all sampling sites. Conclusions: We found that the culture sensitivity improved as the location of the sample was more proximal. More types of pathogens were detected in samples taken from proximal parts of the affected nails.